Mumbai (Maharashtra) [India], June 11: Cipla Health, a leading player in consumer healthcare, announced the launch of its latest campaign, 'Cipladine - Aapka Fast Aid Expert', featuring acclaimed ...

Cipla Ltd reported a robust 30% YoY increase in consolidated net profit, reaching Rs 1,222 crore for Q4 FY25, driven by strong sales in India, the US, and Africa.

Cipla beats profit estimates with strong demand for chronic condition drugs, faces supply chain issues for tumour drug.

Cipla Limited on Tuesday announced an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals for the commercialization of clobetasol propionate ophthalmic suspension, 0.05% ...

Cipla enters into exclusive pact with Formosa to distribute ophthalmic drug Under this agreement, Cipla has exclusive rights to market the innovative treatment for post-operative inflammation and ...

Cipla's ophthalmology division is focused on developing therapies and technologies for glaucoma, dry eye disease, ocular infections and retinal diseases.

Cipla Q3 Results: Pharmaceutical major Cipla on Tuesday reported a 49 per cent year-on-year (YoY) increase in its consolidated net profit for the December quarter (Q3 FY25) at Rs 1,574.6 crore, from ...

Cipla receives approval to market Afrezza, a rapid-acting insulin inhaler, offering a needle-free solution for diabetes management.

Cipla share price: Cipla Ltd shares fell the most in terms of percentage among all the 50 companies in the NSE Nifty today on Wednesday, October 30, 2024. Cipla share price: Cipla Ltd shares fell ...

Cipla , India's third-largest generic drugmaker by sales, reported a 15.2% rise in second-quarter profit that beat estimates, driven by higher sales of its respiratory and cancer drugs in its key ...

The Granules India stock came under selling pressure as the FDA continued a week-long surprise audit at one of the company’s key facilities.